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Editorial
Penehcyclidine and awareness during anaesthesia: caution with
zero numerators
In this issue of the journal, Wang
et al. [1] make the extraordinary
claim that a novel anticholinergic
drug, penehcyclidine hydrochloride
(PHC), can reduce, if not abolish, the
occurrence of accidental intra‐opera-
tive awareness with explicit recall
(subsequently referred to as ‘recall')
[2]. In a placebo group of 452
patients, five experienced recall com-
pared with 0/456 in the PHC group.
A note on the scientific motivation
for this study is warranted. Acetyl-
choline is produced by neuronal
subpopulations in the basal forebrain
and the laterodorsal/pedunculopon-
tine tegmentum in the pons [3]. It is
well known that states of cortical
activation (e.g. during waking or
rapid eye movement sleep) are asso-
ciated with high cholinergic tone;
acetylcholine also plays a role in
memory. As such, the effects of an
anticholinergic drug such as PHC
could conceivably suppress con-
sciousness and memory formation.
Penehcyclidine hydrochloride is
not available in the UK or the USA,
but before readers rush to the inter-
net to order supplies, it is worth
considering some of the limitations
of Wang et al.’s paper. We served
as reviewers of the original submis-
sion and although we raised some
of the points below in criticism,
other reviewers favoured publication
of this research. Disagreements of
this sort are a healthy aspect of peer
review and we were invited to offer
readers an alternative viewpoint.
Our main concerns revolve around
the methodology and the statistics –
the readers are left to judge the
impact that Wang et al.’s paper
should have on clinical practice.
Methodological caution
One salient methodological concern
in the work of Wang et al. relates
to the rates of recall used as the
basis for the power calculation.
Large prospective studies in the US
[4, 5] and Europe [6] have consis-
tently established a rate of recall
between 1 and 2 per 1000. How-
ever, as Wang et al. note, in China
the rate of recall may be consider-
ably higher, ranging from 4 to 10
per 1000 in patients at all risk levels
and almost 50 per 1000 after car-
diac surgery [7–9]. Wang et al.
report that their power analysis was
based on two of these studies,
which assessed two distinct risk
populations with rates at the
extremes of this range, separated by
one order of magnitude (0.41% and
4.7%). For their power calculation
they additionally cite the work of
Groesdonk et al. [10], which found
a zero rate of true recall in 534 fast‐
track cardiac surgery patients, and
Elhakim et al. [11], which found a
rate of 2/25 (8%) after thor-
acic surgery. It is unclear how
Wang et al. determined a single rate
of recall from these diverse studies,
some of which were obviously not
intended to result in epidemiologic
data. Furthermore, three of the four
studies they cite focused on cardio-
thoracic patients and are unlikely to
be applicable to women undergoing
breast surgery with total intrave-
nous anaesthesia (TIVA), which
was the population chosen by
Wang et al.
Both groups in the cohort stud-
ied by Wang et al. had anaesthetic
dose targeted to a Bispectral Index
(BIS) value between 40 and 60, with
patients outside of this range (for
two consecutive values) excluded.
Notably, two patients in the PHC
group were excluded for this reason
(one with a BIS < 40 and one with a
BIS > 60). Had either of these
patients experienced recall, the con-
clusions of the study would have
been radically altered (see below).
For the remainder, 5/452 patients
(1.1%) in the control group reported
recall despite their BIS values
remaining within the acceptable
range as defined in this study.
Although patients receiving TIVA
may be at higher risk for recall [12],
these findings are not consistent with
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a large, multicentre, randomised
controlled trial conducted on TIVA
and BIS in China. Zhang et al.
reported that 0.65% of patients
receiving TIVA without BIS moni-
toring had recall, while those with
BIS monitoring had a rate of 0.14%
[13]. It is extremely surprising (and
difficult to explain) that a comparable
population (Chinese surgical patients
with BIS monitoring), could exhibit a
rate of recall an order of magnitude
lower than that reported by Wang et
al. Although the authors used a com-
mittee of three experts to assess if any
recall represented ‘definite', ‘possible'
or ‘no' awareness, they do not clearly
present how many patients fell into
which category (though we must
assume that all of the five patients
reported were classed as ‘definite').
Finally, Wang et al.’s methodol-
ogy was confined to two interviews,
one postoperatively and one at up
to 48 h after surgery. Most studies
employ a third interview from one
week to one month after surgery,
that might detect recall more often
[4, 6]. This is especially important
to consider since, in one group, a
zero numerator was obtained.
Statistical caution
The main concerns here are encap-
sulated in the penultimate paragraph
of Wang et al.’s paper; namely, that
the authors found a ‘zero numerator'
and also applied a ‘one‐tailed test'.
On the problem of zero
numerators
Zero numerators are much beloved
of some aspirant authors and the
problems they cause to data inter-
pretation have been discussed exten-
sively in the pages of this journal and
elsewhere [14–17]. A researcher may
conduct an observational study or a
comparative trial of an intervention
and find that, in the test group of
interest, there are no complications
or failures at all (i.e. the zero numer-
ator). The researcher will therefore
conclude that the intervention was
extremely favourable. Wang et al.
did this comparing two ratios: 0/456
and 5/452 and found, unsurprisingly,
that they are different (p = 0.03;
one‐tailed Fisher’s exact test).
For reasons previously explained
in some detail [17], this conclusion is
rarely, if ever, correct. Whenever
there is a zero numerator, what really
matters is the upper limit of the 95%
confidence interval (in this case,
using binomial confidence intervals).
For the data of Wang et al., this upper
limit of 0/456 is in fact 3.7/456
(rounded up to 4/456), so it is this
incidence that should form the basis
of any comparison (which would not
be statistically significant: p = 0.495,
one‐tailed Fisher’s exact test).
This approach is emphasised in
the so‐called ‘rule of three', which
states that whenever there is a zero
numerator, or whenever no compli-
cations or failures are observed, out
of n observations, the upper 95% CI
limit for the ‘true' rate is approxi-
mately 3/n; a simple approach that
has its limitations [18], but is often
surprisingly accurate [14, 15] (for
Wang et al.’s dataset, the 95% CI is
closer to 4, not 3).
In fact, Wang’s data are exqui-
sitely sensitive to the rate of recall in
the test group. The ‘rule of three' is
overkill for their data; even if just
one patient in the PHC group expe-
rienced recall, the comparison jumps
from a ‘significant' p = 0.03 to a
‘non‐significant' p = 0.107. Given
our methodological concerns out-
lined above, it is not difficult to
imagine either that the rate of recall
in the PHC group was underesti-
mated, or that the rate in the control
group was overestimated.
On the dilemma of tails
Wang et al. performed a one‐tailed
statistical comparison on their data.
A ‘tail' can be understood by imag-
ining a graph of the data distribu-
tion (i.e. a histogram of the
frequency of an observation’s occur-












Figure 1 A normal distribution curve with the two tails (each representing
 2.5% of the data points) shown in blue.
Anaesthesia 2013, 68, 121–135 Editorial
132 Anaesthesia © 2012 The Association of Anaesthetists of Great Britain and Ireland
The normal distribution is well
known, and the data points at the
very limits of the curve at either
end form the two ‘tails'. A two‐
tailed comparison tests for the pos-
sibility of a relationship in both
directions. For example, we may
wish to compare the mean of a
sample against a given value x using
a t‐test. Our null hypothesis is that
the mean = x. A two‐tailed compar-
ison will test whether the mean is
both significantly > x and signifi-
cantly < x. In the calculation, values
from both ‘tails' are used.
On the other hand, a one‐tailed
comparison tests for the possibility of
a relationship only in one direction
and completely disregards the possi-
bility of a relationship in the other
direction. In the example above,
comparing the mean of a sample
against x, a one‐tailed comparison
tests whether the mean is signifi-
cantly > x or significantly < x, but not
both possibilities at once. A one‐
tailed comparison thus provides
more power to detect an effect in one
direction by not testing the effect in
the other direction.
It is possible to justify the use of
one‐tailed comparisons in some cir-
cumstances, especially where the
overall direction of intervention is
itself not in doubt, but the magni-
tude of effect may be of more inter-
est. The choice of test should be
based on the hypothesis so that for
novel, unusual therapies about which
very little is known (such as PHC),
where the intervention could result
in a change in either direction, a
two‐tailed comparison would usually
be regarded as essential [19–22].
The use of two‐tailed compari-
sons in Fisher’s exact test requires a
little explanation. The contribution
of Fisher to statistics has been dis-
cussed before in the pages of this
journal [23]. His ‘exact test' was
originally designed to assess if a col-
league could tell whether milk or tea
had been poured first into her cup,
and it follows a hypergeometric dis-
tribution (Fig. 2). This is the distri-
bution obtained when performing
binomial sampling without replace-
ment; for example, the probabilities
of obtaining 0, 1, 2, 3, 4 and 5 white
balls from an urn of 15 red and 5
white balls. Fig. 2 shows that this
distribution is, unlike the normal
distribution, unequal in its tails.
With a zero numerator, the
data of Wang et al. were at one
extreme of this distribution. Table 1
shows the data of Wang et al. dis-
played in a 2 9 2 format. The val-
ues in the top row are 0 vs 5.
Theoretically more extreme ratios
would be 0 vs 6, 0 vs 7, 0 vs 8,…0
vs 452 (Table 1; red text). The one‐
sided comparison that Wang et al.
made tested whether 0/456 is less
than 5/452, 6/452, 7/452,…452/452,
which of course it is. Had they con-
ducted a two‐tailed test, they would
have additionally examined the
comparison of less extreme ratios;
namely 0/456 vs 4/452, 3/452,
Figure 2 Hypergeometric distribution. In an urn of 15 red and 5 white
balls, a sample of 5 balls is taken without replacement; the graph shows the
probability of obtaining 0, 1, 2, 3, 4 and 5 white balls in the sample. Note
the asymmetric distribution.
Table 1 The data of Wang et al. laid out in a 2 9 2 table. Numbers in
black are Wang et al.’s reported data; numbers in red offer an example of
the single (more extreme) tail that they used in their one‐tailed test. Num-
bers in blue represent a less extreme tail, the probabilities for which would
be included in a two‐tailed test.
PHC Control
Aware 0,1,2,3,4 ? 5 ? 6,7,8….452 0
Not aware 452,451,…? 447 ? 446,445,….0 456
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2/452, 1/452 and 0/452 (Table 1;
blue text). For Fisher’s exact test, a
two‐tailed comparison may not
always yield a p value exactly dou-
ble that of a one‐sided comparison,
but in this case, a proper, two‐tailed
comparison of the data in Table 1
yields a p value of 0.062, which is
non‐significant.
Summary
“Le poids de la preuve pour
une affirmation extraordinaire
doit Átre proportionnel à son
degré d'étrangeté''
Marquis de Laplace [24]
Extraordinary claims need extraordi-
nary evidence. Statistical significance
(the p value) is in part an index of
how confident we should be about
the ‘reality' of suggested differences.
For significance obtained using a
one‐sided test that remains even
when using a two‐sided test, we can
be fairly confident that any differ-
ences reported are likely and consis-
tently ‘real'. Significance obtained
using a one‐sided test that disappears
when using a two‐sided test should
raise more than a kernel of doubt.
The methodological shortcom-
ings may have missed some cases of
recall in Wang et al.’s test group,
and so led to the problem of a zero
numerator in the PHC group. This
was coupled with an unusually high
rate of recall in the control group.
Then, the only way that Wang et
al. could obtain a significant result
for PHC’s effect was by performing
a one‐tailed test. If they had
used any numerator other than 0
(e.g. applied the rule of three),
or applied binomial confidence
intervals, or correctly used a two‐
tailed comparison, the significant
effect of PHC simply disappears. It
is indeed an extraordinary claim to
suggest that a single drug, used
empirically, can eliminate recall
after general anaesthesia. The evi-
dence in support of that suggestion
needs to be far more extraordinary,
in our opinion, than has been pre-
sented by Wang et al. Nonetheless,
it is an interesting idea and we look
forward to further work in this
compelling area of research.
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